2月3日，武汉友芝友生物制药股份有限公司（02496.HK）宣布，其研发的M701已获得美国食品药品监督管理局（FDA）的新药临床试验申请（IND）批准。此次获批标志着该药物可进入临床开发阶段，为公司创新药管线的国际化布局奠定重要基础。
2月3日，武汉友芝友生物制药股份有限公司（02496.HK）宣布，其研发的M701已获得美国食品药品监督管理局（FDA）的新药临床试验申请（IND）批准。此次获批标志着该药物可进入临床开发阶段，为公司创新药管线的国际化布局奠定重要基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.